A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending Single Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TG-0054 in Healthy Subjects
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Burixafor (Primary)
- Indications Stem cell mobilisation
- Focus Adverse reactions; Therapeutic Use
- Sponsors GPCR Therapeutics; TaiGen Biotechnology
Most Recent Events
- 23 May 2014 New trial record